title: Sarpogrelate treatment reduces restenosis after coronary stenting.
abstract: BACKGROUND
  Sarpogrelate, a serotonin blocker, has been reported to inhibit the serotonin-induced proliferation of rat aortic smooth muscle cells. The aim of this study was to investigate whether sarpogrelate reduces restenosis after coronary stenting as a result of prevention of intimal hyperplasia.
  
  
  METHODS
  We examined 79 patients with stable angina undergoing elective coronary stenting on de novo lesions of native coronary arteries in a prospective, randomized trial. All enrolled patients received aspirin and ticlopidine, and one third of the patients were assigned to receive oral sarpogrelate.
  
  
  RESULTS
  Treatment with sarpogrelate in addition to aspirin and ticlopidine caused no major adverse cardiovascular events or hemorrhagic adverse effects during the 6-month follow-up period. The restenosis rate in the group of patients receiving sarpogrelate was 4.3%, which was significantly lower than the 28.6% rate found in the group of patients not receiving sarpogrelate.
  
  
  CONCLUSIONS
  Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis.
authors.affiliation: College of Medical Technology, Kyoto University, Kyoto, Japan. mfujita@kuhp.kyoto-u.ac.jp
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Fujita
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Mizuno
authors.forename: Mami
authors.initials: M
authors.lastname: Ho
authors.forename: Reiko
authors.initials: R
authors.lastname: Tsukahara
authors.forename: Akira
authors.initials: A
authors.lastname: Miyamoto
authors.forename: Osamu
authors.initials: O
authors.lastname: Miki
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Ishii
authors.forename: Kunihisa
authors.initials: K
authors.lastname: Miwa
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000000981:diagnostic imaging / Q000601:surgery*; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D011446:Prospective Studies; D012702:Serotonin Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D013386:Succinates / Q000494:pharmacology / Q000627:therapeutic use*; D013988:Ticlopidine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D012702:Serotonin Antagonists; D013386:Succinates; C064294:sarpogrelate; D013988:Ticlopidine; D001241:Aspirin